Literature DB >> 15181491

Salmonella enterica serotype Choleraesuis infection in a medical center in northern Taiwan.

Shun Chiu1, Cheng-Hsun Chiu, Tzou-Yien Lin.   

Abstract

This retrospective study was conducted in order to determine the clinical and microbiologic features of infection with Salmonella enterica serotype Choleraesuis. Between March 1999 and December 2002, 55 patients with 66 isolates were enrolled for analysis. The ratio of males to females was 2.2:1. Most patients were older than 60 years (56%) and had underlying diseases (78%), such as diabetes mellitus, malignancy, and peptic ulcer. Fever (85%) was the most common clinical manifestation, followed by abdominal pain/fullness (31%). The gastrointestinal manifestations, including nausea/vomiting or diarrhea, accounted for only 13% and 11% of patients, respectively. S. enterica serotype Choleraesuis was extremely invasive, with a high predilection to cause bacteremia (78% of the isolates were from blood). Various types of metastatic focal infections were found, including infected arterial aneurysm, osteomyelitis, septic arthritis, urinary tract infection and wound infection. The crude mortality rate was 18% (10 deaths in 55 cases). Nearly all isolates were susceptible to the third-generation cephalosporins. A higher resistance rate to commonly used antimicrobial agents was found with ampicillin (85%, 56/66), trimethoprim-sulfamethoxazole (81%, 40/49), chloramphenicol (96%, 47/49), and ciprofloxacin (49%, 30/61). In view of the emergence of fluoroquinolone resistance, the third-generation cephalosporins appear to be the best choice for treatment of invasive infections caused by this organism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15181491

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  7 in total

Review 1.  Glycoconjugate vaccine strategies for protection against invasive Salmonella infections.

Authors:  Raphael Simon; Myron M Levine
Journal:  Hum Vaccin Immunother       Date:  2012-02-28       Impact factor: 3.452

2.  Epidemiologic relationship between fluoroquinolone-resistant Salmonella enterica Serovar Choleraesuis strains isolated from humans and pigs in Taiwan (1997 to 2002).

Authors:  Chao-Chin Chang; Yi-Hsuan Lin; Chao-Fu Chang; Kuang-Sheng Yeh; Cheng-Hsun Chiu; Chishih Chu; Maw-Sheng Chien; Yuan-Man Hsu; Li-Shu Tsai; Chien-Shun Chiou
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

3.  Bacteraemia due to ciprofloxacin-resistant Salmonella enterica serotype Choleraesuis in adult patients at a university hospital in Taiwan, 1996-2004.

Authors:  J-Y Wang; J-J Hwang; C-N Hsu; L-C Lin; P-R Hsueh
Journal:  Epidemiol Infect       Date:  2006-03-29       Impact factor: 2.451

4.  Antimicrobial Resistance and Molecular Investigation of H2S-Negative Salmonella enterica subsp. enterica serovar Choleraesuis Isolates in China.

Authors:  Jing Xie; Shengjie Yi; Jiangong Zhu; Peng Li; Beibei Liang; Hao Li; Xiaoxia Yang; Ligui Wang; Rongzhang Hao; Leili Jia; Zhihao Wu; Shaofu Qiu; Hongbin Song
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

5.  An association of genotypes and antimicrobial resistance patterns among Salmonella isolates from pigs and humans in Taiwan.

Authors:  Hung-Chih Kuo; Tsai-Ling Lauderdale; Dan-Yuan Lo; Chiou-Lin Chen; Pei-Chen Chen; Shiu-Yun Liang; Jung-Che Kuo; Ying-Shu Liao; Chun-Hsing Liao; Chi-Sen Tsao; Chien-Shun Chiou
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

6.  Salmonella enterica Serotype Choleraesuis Infection of the Knee and Femur in a Nonbacteremic Diabetic Patient.

Authors:  Alexander M Sy; Jagbir Sandhu; Theodore Lenox
Journal:  Case Rep Infect Dis       Date:  2013-05-28

7.  Salmonella-Infected Aortic Aneurysm: Investigating Pathogenesis Using Salmonella Serotypes.

Authors:  Chishih Chu; Min Yi Wong; Cheng-Hsun Chiu; Yuan-Hsi Tseng; Chyi-Liang Chen; Yao-Kuang Huang
Journal:  Pol J Microbiol       Date:  2019-10-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.